All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Bookmark this article
A retrospective analysis on the safety and efficacy of carmustine, etoposide, cytarabine, and cyclophosphamide (BEAC) conditioning in autologous hematopoietic cell transplantation (AHCT) in both Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), was recently published in Bone Marrow Transplantation, by Ioanna Sakellari from George Papanikolaou Hospital, Thessaloniki, GR, and colleagues.
Finding the safest and most efficient AHCT conditioning regimen is crucial in lymphomas. Carmustine, etoposide, cytarabine, and melphalan (BEAM) is the most frequently used conditioning in NHL and HL. Nevertheless, availability issues with melphalan and carmustine have led to the introduction of BEAC and busulfan EM (BuEM), respectively, as potential replacements. The aim of this study was to retrospectively compare the efficacy and safety of BEAC versus BuEM in both NHL and HL patients.
The results of this retrospective analysis indicate that BEAC is a safer AHCT conditioning regimen than BuEM in HL and NHL patients. Both BEAC and BuEM resulted in similar outcomes in NHL and HL patients, therefore further supporting the authors’ recommendation for using BEAC as an alternative conditioning regimen in lymphomas.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox